542 related articles for article (PubMed ID: 15121300)
61. The mouse intranasal challenge model for potency testing of whole-cell pertussis vaccines.
Queenan AM; Fernandez J; Shang W; Wiertsema S; van den Dobbelsteen GP; Poolman J
Expert Rev Vaccines; 2014 Oct; 13(10):1265-70. PubMed ID: 25029905
[TBL] [Abstract][Full Text] [Related]
62. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis.
Taranger J; Trollfors B; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
J Infect Dis; 2000 Mar; 181(3):1010-3. PubMed ID: 10720524
[TBL] [Abstract][Full Text] [Related]
63. [Seroepidemiological studies on the immunization of the population against species of the genus Bordetella in 1996-1997].
Mihai G; Alecu V; Neagu A
Bacteriol Virusol Parazitol Epidemiol; 1998; 43(3):157-60. PubMed ID: 9932004
[No Abstract] [Full Text] [Related]
64. Bordetella pertussis isolates in Finland: serotype and fimbrial expression.
Heikkinen E; Xing DK; Olander RM; Hytönen J; Viljanen MK; Mertsola J; He Q
BMC Microbiol; 2008 Sep; 8():162. PubMed ID: 18816412
[TBL] [Abstract][Full Text] [Related]
65. Roads to the development of improved pertussis vaccines paved by immunology.
Brummelman J; Wilk MM; Han WG; van Els CA; Mills KH
Pathog Dis; 2015 Nov; 73(8):ftv067. PubMed ID: 26347400
[TBL] [Abstract][Full Text] [Related]
66. Population dynamics of Bordetella pertussis in Finland and Sweden, neighbouring countries with different vaccination histories.
Elomaa A; Advani A; Donnelly D; Antila M; Mertsola J; He Q; Hallander H
Vaccine; 2007 Jan; 25(5):918-26. PubMed ID: 17030495
[TBL] [Abstract][Full Text] [Related]
67. Heterologous prime-boost immunization with live attenuated B. pertussis BPZE1 followed by acellular pertussis vaccine in mice.
Feunou PF; Kammoun H; Debrie AS; Locht C
Vaccine; 2014 Jul; 32(34):4281-8. PubMed ID: 24950361
[TBL] [Abstract][Full Text] [Related]
68. Do Pertussis Vaccines Protect Against Bordetella parapertussis?
Liko J; Robison SG; Cieslak PR
Clin Infect Dis; 2017 Jun; 64(12):1795-1797. PubMed ID: 28369240
[TBL] [Abstract][Full Text] [Related]
69. Protection and humoral immune responses against Bordetella pertussis infection in mice immunized with acellular or cellular pertussis immunogens.
van den Berg BM; David S; Beekhuizen H; Mooi FR; van Furth R
Vaccine; 2000 Dec; 19(9-10):1118-28. PubMed ID: 11137247
[TBL] [Abstract][Full Text] [Related]
70. Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children.
Hallander HO; Ljungman M; Storsaeter J; Gustafsson L
APMIS; 2009 Nov; 117(11):797-807. PubMed ID: 19845530
[TBL] [Abstract][Full Text] [Related]
71. Acellular Bordetella pertussis vaccine enhances mucosal interleukin-10 production, induces apoptosis of activated Th1 cells and attenuates colitis in Galphai2-deficient mice.
Ohman L; Willén R; Hultgren OH; Hultgren Hörnquist E
Clin Exp Immunol; 2005 Jul; 141(1):37-46. PubMed ID: 15958068
[TBL] [Abstract][Full Text] [Related]
72. Pertussis before and after the introduction of acellular pertussis vaccines in Finland.
Elomaa A; He Q; Minh NN; Mertsola J
Vaccine; 2009 Sep; 27(40):5443-9. PubMed ID: 19628060
[TBL] [Abstract][Full Text] [Related]
73. Mouse and pig models for studies of natural and vaccine-induced immunity to Bordetella pertussis.
Mills KH; Gerdts V
J Infect Dis; 2014 Apr; 209 Suppl 1():S16-9. PubMed ID: 24626866
[TBL] [Abstract][Full Text] [Related]
74. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis.
Mills KH; Ryan M; Ryan E; Mahon BP
Infect Immun; 1998 Feb; 66(2):594-602. PubMed ID: 9453614
[TBL] [Abstract][Full Text] [Related]
75. Comparative analysis of a Bordetella pertussis patient isolated strain and classical strains used in the pertussis vaccine.
Pereira A; Pereira AS; Moreira-Filho CA; Bando SY; Tambourgi DV
Vaccine; 2005 Jul; 23(34):4353-8. PubMed ID: 16005744
[TBL] [Abstract][Full Text] [Related]
76. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough.
Mielcarek N; Debrie AS; Raze D; Bertout J; Rouanet C; Younes AB; Creusy C; Engle J; Goldman WE; Locht C
PLoS Pathog; 2006 Jul; 2(7):e65. PubMed ID: 16839199
[TBL] [Abstract][Full Text] [Related]
77. Acellular pertussis vaccine composed of genetically inactivated pertussis toxin.
Peppoloni S; Pizza M; De Magistris MT; Bartoloni A; Rappuoli R
Physiol Chem Phys Med NMR; 1995; 27(4):355-61. PubMed ID: 8768791
[TBL] [Abstract][Full Text] [Related]
78. Mixed outbreak of Bordetella pertussis and Bordetella parapertussis infection in Finland.
Mertsola J
Eur J Clin Microbiol; 1985 Apr; 4(2):123-8. PubMed ID: 2861090
[TBL] [Abstract][Full Text] [Related]
79. Reactogenicity of infant whole cell pertussis combination vaccine compared with acellular pertussis vaccines with or without simultaneous pneumococcal vaccine in the Netherlands.
David S; Vermeer-de Bondt PE; van der Maas NA
Vaccine; 2008 Oct; 26(46):5883-7. PubMed ID: 18775463
[TBL] [Abstract][Full Text] [Related]
80. Protective effects of in vivo-expressed autotransporters against Bordetella pertussis infection.
Suzuki K; Shinzawa N; Ishigaki K; Nakamura K; Abe H; Fukui-Miyazaki A; Ikuta K; Horiguchi Y
Microbiol Immunol; 2017 Sep; 61(9):371-379. PubMed ID: 28752940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
